People exposed to asbestos often develop lung disease in later life; manifestations include benign, malignant, or diffuse interstitial lung disease. This evidence based review covers who is considered to be at risk, different ways that exposure to asbestos affect the lung, and matters relating to compensation. Because many doctors in primary and secondary care encounter patients who have been exposed to asbestos, they need to be aware of how different people can be affected.
who is at risk of asbestos related lung disease?
All people who have worked with asbestos are at potential risk of asbestos related lung disease through inhalation of fibres. Asbestos is a mineral silicate that occurs naturally in various forms. It is resistant to heat and other means of destruction, which explains its extensive use during the 19th and 20th centuries. The fibrous nature of asbestos allows it to be woven into cloth or incorporated into cement materials, ceiling tiles, brake and clutch linings, pipe and boiler insulation, flooring, resins, polymers, and filter papers.
Historically, people with the highest exposures worked in asbestos mining, milling, and production of asbestos textiles. Countries that currently produce large amounts of asbestos include Russia, Kazakhstan, China, and Canada. In the 1920s to 1940s asbestosis developed in textile workers with a latency of only a few years and progressed rapidly to death, because exposure was high.
1 w1 w2 The risk to people using asbestos products was recognised in shipyard workers in the 1950s, and an association with mesothelioma was determined in the 1960s through a case-control study in South African miners. 2 However, one of the first suggestions that exposure to asbestos can cause lung disease was in 1899 in an industrial diseases board of enquiry.
3 Today, most people with asbestos related lung disease have a clear history of exposure, such as mixing asbestos cement or fitting insulation (builders), working with asbestos insulation materials (plumbers and electricians), or cutting asbestos cement sheet materials, although some may have been exposed without their knowledge (for example, shipyard workers or ship engineering workers). The lifetime risk of developing mesothelioma was highlighted in a recent study in which joiners, plumbers, electricians, painters, and construction workers had a greater likelihood of being diagnosed within the general population. 4 The occurrence of asbestos related lung disease in spouses who laundered the clothing of workers exposed to asbestos is also well established.
5 A detailed occupational history-to determine the occupation, what it involved, dates of employment, and length of asbestos exposure-is therefore important in all patients presenting with respiratory symptoms.
w3 Because of the unregulated use of asbestos in developing countries, the incidence of asbestos related lung disease worldwide is likely to rise significantly in the years ahead.
How does asbestos affect the lung?
The shape of asbestos fibres results in their retention within the lung. Clearance from the lung occurs by the mucociliary ladder and phagocytic ingestion by macrophages or endocytosis by pneumocytes, but migration to the pleural surface can occur via the lymphatic system. 6 The common forms of asbestos exist as serpentine curved fibres (chrysotile (white)) or amphibole straight 
SummaRy pointS
The risk of asbestos related lung disease is dose related and depends on fibre type Joiners, plumbers, electricians, painters, shipyard workers, builders, engineers, and asbestos miners are at greatest risk Asbestos exposure can cause benign disease (pleural plaques, pleural thickening, benign pleural effusions), malignant disease (mesothelioma, lung cancer), and interstitial lung disease (asbestosis) Mesothelioma will peak in incidence between 2011 and 2015; it should be considered in all patients with a pleural effusion, chest pain, and history of asbestos exposure Treatment options in asbestosis are limited Some patients are entitled to compensation and should seek advice from the Department of Work and Pensions or dedicated charity organisations
SourCeS and SeleCtion Criteria
We comprehensively searched articles published up to February 2009 using PubMed and Medline. Key words and phrases used were "asbestos", "malignant mesothelioma", "pleural plaques", "pleural thickening", "asbestosis", "lung cancer", "cigarette smoking", "pleural effusions", "compensation", "occupation", "chemotherapy", "radiotherapy", "surgery", "treatment", and "survival" what sort of lung disease can asbestos cause? Benign pleural disease Pleural plaques Pleural plaques consist of layers of hyalinised collagen fibres usually found on the parietal pleura, and they occur in 20-60% of people who have been exposed to asbestos. 7 w5 They most commonly appear as calcified areas adjacent to the sixth to ninth ribs and along the surface of the diaphragm, but they tend not to be evident at the lung apices or costophrenic angles. Pleural plaques can usually be identified on a chest radiograph (fig 1) , although computed tomography is more sensitive and distinguishes them from solid tumours if the diagnosis is uncertain. They do not undergo malignant change or generally cause symptoms, although pleural plaques have been associated with anginal pain. 8 Diffuse pleural thickening Diffuse thickening of the pleura is less specific to asbestos exposure than pleural plaques. It may occur after exposure to asbestos, but other causes include previous haemothorax, tuberculosis, chest surgery, radiation, infection, and exposure to drugs such as methysergide. Diffuse pleural thickening on a chest radiograph is characterised by a smooth continuous pleural density affecting at least 25% of the lateral chest wall, with or without blunting of the costophrenic angle.
w6 It has also been defined on computed tomography as a continuous sheet of pleural thickening (>5 cm wide, >8 cm in craniocaudal extent, and >3 mm thick).
9 In extensive diffuse pleural thickening, patients may become breathless and have a restrictive ventilatory defect on lung function tests. In diffuse thickening (which is usually bilateral), the pleura will appear smooth, and the mediastinal border will be unaffected, whereas in mesothelioma, the pleura is likely to be unilaterally irregularly thickened and the mediastinal border affected. If the diagnosis is uncertain, computed tomography and biopsy are warranted.
Benign asbestos related pleural effusion
Benign exudative pleural effusions are often preceded by episodes of "asbestos pleurisy." They can occur within 15 years of asbestos exposure 10 but may also appear much later.
w7 Because of confusion with a malignant effusion, a pleural biopsy is usually needed, and this shows non-specific inflammation. Benign effusions may resolve spontaneously (often leaving an area of pleural thickening) or require drainage if large enough to cause symptoms.
Interstitial lung disease Asbestosis
Asbestosis is caused by inhalation of asbestos fibres and is a typical pneumoconiosis (interstitial lung disease caused by inhaled inorganic dusts). The condition is directly related to the magnitude and duration of exposure to asbestos.
11 After a latent period of 20-30 years, patients with developing asbestosis experience an insidious onset of breathlessness and reduced exercise tolerance; cough, sputum production, and wheezing are less common. As the condition progresses, fine bilateral inspiratory crackles, finger clubbing, and cor pulmonale may occur. Data from the Health and Safety Executive indicated that 111 deaths in the United Kingdom in 2006 were caused by asbestosis, and that 393 death certificates mentioned asbestosis (www.hse.gov.uk/statistics/causdis/asbestosis/ index.htm).
Pulmonary function tests show reduced gas transfer, reduced lung volumes, a restrictive ventilatory defect, and exercise related hypoxaemia. Chest radiography may be normal, 12 but usually shows bilateral lower zone interstitial changes, often with pleural plaques and thickening. High resolution computed tomography is a more sensitive tool (fig 2) , and characteristic features include coarse parenchymal bands, subpleural linear densities, interstitial fibrotic change, and honeycombing in advanced disease. 13 In contrast to idiopathic pulmonary fibrosis, confluent ground glass changes are rare in asbestosis, whereas thick band-like opacities are more common w8 ; the most discriminatory feature is concomitant pleural disease in asbestosis. Histological evidence is not necessary for the diagnosis to be made: typical clinical features along with previous asbestos exposure, consistent pulmonary function abnormalities, inte rstitial fibrosis 
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(with no alternative explanation), plus other radiographic changes seen after exposure to asbestos are usually adequate. No specific treatment is available other than that for chronic obstructive pulmonary disease and cor pulmonale if present, smoking cessation, and prevention of further exposure to asbestos. The prognosis of asbestosis is highly variable and depends on the extent of lung involvement and severity of coexisting chronic obstructive pulmonary disease and presence of other comorbidities.
Malignant disease Lung cancer
Exposure to asbestos causes lung cancer independently of cigarette smoking.
14 w9 In an analysis of 23 epidemiological studies, asbestos exposure increased the risk of lung cancer by a similar factor in non-smokers and smokers, with a synergistic (multiplicative) interaction seen between asbestos exposure and cigarette smoking.
14 Even in the absence of asbestosis, very heavy asbestos exposure may cause lung cancer.
w10 Lung cancer should be considered in patients with asbestosis who have haemoptysis, worsening cough, chest pain and breathlessness, weight loss, and anorexia. Diagnostic and management strategies are the same as those for lung cancer in general (www.sign.ac.uk; www.nice.org.uk).
Mesothelioma
Malignant mesothelioma is an aggressive pleural tumour with increasing incidence.
15 16 Data from the UK mesothelioma register indicated that the annual number of deaths from mesothelioma had risen from 153 in 1968 to 1848 in 2001, and it is predicted to peak at 1950-2450 cases annually between 2011 and 2015.
17 In 2006, the UK Health and Safety Executive gave the number of deaths from mesothelioma on death certificates as 2056 (85% male; www.hse.gov.uk/statistics/causdis/mesothelioma/). However, official mortality data may underestimate the extent by 10%. In one well conducted study of 622 patients with mesothelioma (512 men), disease was caused by occupational or domestic asbestos exposure in 86% of men and 38% of women. Around half of the men were construction workers, and only four had worked for more than five years in the manufacture of asbestos products. 4 The lag period between initial exposure and death varies, but one retrospective analysis (1105 patients with definite mesothelioma) found a median latency of 32 years, with 96% of cases occurring after at least 20 years.
w12
Focus on mesothelioma The diagnosis of malignant mesothelioma is based on a combination of clinical, radiological, and histological features. However, a clear histological diagnosis removes any uncertainty and makes compensation claims more straightforward.
Clinical presentation
British Thoracic Society guidelines suggest that malignant mesothelioma should be considered in any patient with a pleural effusion or pleural thickening, especially if a history of asbestos exposure and chest pain is present.
15 Characteristically, the pain is dull, diffuse, progressive, and occasionally pleuritic. Breathlessness may be caused by a pleural effusion or circumferential pleural thickening. Patients may also present with a palpable chest wall mass, finger clubbing (usually caused by underlying asbestosis), and features of a pericardial effusion caused by local extension in progressive disease. Ascites caused by peritoneal mesothelioma and secondary hydropneumothorax are uncommon but recognised presentations.
Investigations
Chest radiography and computed tomography may show a pleural effusion, lobulated or nodular pleural changes, a pleural mass, rib destruction, chest wall involvement, or a small hemithorax as a result of lung entrapment ( fig 3) ; other features of exposure to asbestos may also be present.
Pleural fluid in patients with mesothelioma is straw coloured or blood stained. Cytological analysis of pleural fluid occasionally leads to the diagnosis, although a pleural biopsy is usually needed. Percutaneous pleural biopsy has historically been performed using an Abram's 15 For example, in one study, 50 patients with a cytologically negative (although suspected malignant) pleural effusion were randomised to either Abram's pleural biopsy or computed tomography guided biopsy.
20
The first method correctly diagnosed malignancy in eight of 17 patients (sensitivity 47%, specificity 100%), whereas computed tomography guided biopsy diagnosed malignancy in 13 of 15 (sensitivity 87%, specificity 100%; difference in sensitivity between procedures 40%, 95% confidence interval 10% to 69%, P=0.02). An alternative surgical diagnostic procedure consists of a video assisted thoracoscopic approach that allows multiple biopsies to be taken under direct visualisation; this technique also allows talc pleurodesis to be performed at the same time if malignancy is highly likely. Thoracoscopy under local anaesthetic (enabling drainage of pleural fluid, biopsy, and pleurodesis) is becoming increasingly available across the UK and may be carried out by appropriately trained physicians.
Treatment
Patients with mesothelioma should be discussed at a lung multidisciplinary team meeting (comprising chest physicians, surgeons, radiologists, pathologists, oncologists, and specialist nurses; see box).
15 w13 Although the benefits are uncertain, prophylactic radiotherapy to the pleural puncture site is often considered in patients who have had large chest wall incisions (during thoracoscopy or insertion of a large bore chest tube) to reduce the chance of tumour cells seeding along the track to the skin surface.
21
Palliative chemotherapy is offered to fit patients, despite a paucity of data showing any survival advantage. In one study, 448 patients were randomised to receive pemetrexed plus cisplatin or cisplatin alone. Median survival with permetrexed and cisplatin was 12 months versus nine months with cisplatin alone (P=0.002).
22 In another study of 250 patients, 23 raltitrexed and cisplatin significantly improved overall survival compared with cisplatin alone, although no differences in quality of life were seen, and the study had no placebo arm. The role of surgery is controversial, 24 but recent data suggest that extrapleural pneumonectomy is not useful in the management of mesothelioma 25 ; however, the results of other trials are awaited (MesoVATS and MARS2). Lung sparing debulking procedures are now gaining popularity and should be considered for patients within the context of randomised trials.
The prognosis of malignant mesothelioma-especially in older men who are unfit and have peritoneal mesothelioma and sarcomatoid histology-is poor. The median survival in a variety of studies is between eight and 14 months from diagnosis. 15 who is entitled to compensation? Patients with asbestos related lung disease may be eligible for compensation through Industrial Injuries Disablement Benefit (IIDB) from the Department for Work and Pensions or a civil law claim for damages from the employer under whose auspices exposure occurred ( inquiry to be held into teenager's death after radiation overdose In this "In brief" News item (BMJ 2009; 339: b3161, print publication 8 Aug, p 314) we wrongly edited the correctly written item. This resulted in the item seeming to suggest (by the phrase "given fatal radiation treatment") that the radiation treatment had caused the girl's death. This is not what we had intended to publish. The first sentence should have read: "A fatal accident inquiry is to be held into the death of a teenage patient with cancer who was given radiation treatment 58% higher than prescribed."
effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials We have received a late correction to this research paper by Giovanni F M Strippoli and colleagues, published early in 2008 (BMJ 2008; 336:645-51, print publication 22 Mar 2008) . Although figures 1 and 2 (both forest plots) were correct at submission, when we redrew them we added the wrong labels to the x axis, and the errors were not picked up during the proof stage. To ensure correct representation of the data, we have redrawn these two figures and linked them to the article on bmj.com as "extra" material (see "Corrected figures" with the online article, doi:10.1136/ bmj.39472.580984.AE). The figures were also wrong in the full (online) version of the article (where they appeared as figures 3 and 4).
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The third author of this obituary (BMJ 2009; 338:b1987, print (48, 65, and 71; and 65, 73, and 84 ) are percentages (not minutes) of time without fever over four hours and 24 hours after the first dose of study drugs respectively. The correct times are in the table.
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